Treatment of psoriasis with crisaborole

Abstract

Crisaborole, a topical phosphodiesterase-4 (PDE4) inhibitor, is effective in patients with atopic dermatitis. As systemic PDE4 inhibition has also been used with success in psoriasis, clinical trials are underway to determine the utility of topical PDE4 inhibitors in these patients. However, there is no current literature documenting use of crisaborole for psoriasis. Here, we present two cases in which patients with psoriasis were treated successfully with crisaborole.

Keywords:

• Psoriasis
• crisaborole
• phosphodiesterase-4

Disclosure statement

Dr Lebwohl is an employee of Mount Sinai which receives research funds from Abbvie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Leo Pharmaceuticals, Mediummune/Astra Zeneca, Novartis, Pfizer, Sciderm, Valeant, and ViDac. Dr Lebwohl is also a consultant for Allergan, Aqua, Boehringer-Ingelheim, LEO Pharma, Menlo, and Promius. Dr Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron. The rest of the authors have no conflicts of interest to disclose.